Tandem Diabetes Care (TNDM) Cash from Investing Activities (2013 - 2026)

Tandem Diabetes Care's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$195.4 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 2227.67% year-over-year to -$195.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$131.8 million (down 1325.95% YoY) and the FY2025 annual result came in at $72.9 million, up 410.35% from the prior year.
• Cash from Investing Activities was -$195.4 million for Q1 2026 at Tandem Diabetes Care, down from -$15.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $58.1 million in Q2 2025 and bottomed at -$195.4 million in Q1 2026.
• A 5-year average of -$11.7 million and a median of -$3.5 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2025 — Cash from Investing Activities surged 1742.09% — and 2026, when it slumped 2227.67%.
• Tandem Diabetes Care's Cash from Investing Activities stood at $35.8 million in 2022, then plunged by 146.35% to -$16.6 million in 2023, then jumped by 130.21% to $5.0 million in 2024, then sank by 398.92% to -$15.0 million in 2025, then tumbled by 1205.07% to -$195.4 million in 2026.
• Business Quant data shows TNDM's Cash from Investing Activities at -$195.4 million in Q1 2026, -$15.0 million in Q4 2025, and $20.5 million in Q3 2025.